Clinical characteristics and prognostic outcomes in KRAS-mutant non-small cell lung cancer: A real-world study with or without COPD comorbidity
COPD-comorbid KRAS-mutant NSCLC patients exhibit unique G12C subtype enrichment and distinct clinical features. Chemoimmunotherapy represents an effective first-line strategy for this population, particularly benefiting those with G12C mutations.
Authors
- Zhi Xu
- Chen Di Liao (ORCID: https://orcid.org/0000-0001-9469-205X)
- Defeng Hu
- Yubo Wang (ORCID: https://orcid.org/0000-0002-3404-0225)
- Yafei Li (ORCID: https://orcid.org/0000-0003-1158-7671)
- Yu Xu
- Jiarui Wang (ORCID: https://orcid.org/0000-0002-0078-2191)
- Huawei Chen (ORCID: https://orcid.org/0000-0002-6037-3808)
- Rui Luo (ORCID: https://orcid.org/0000-0002-5202-0236)
- Zhoukui Bi
- Li Bai (ORCID: https://orcid.org/0000-0002-6283-986X)
Institutions
- Army Medical University (CN)
- Xinqiao Hospital (CN)
- Southwest Hospital (CN)
- Jiangjin Central Hospital (CN)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2025-12-07
- DOI
- https://doi.org/10.1016/j.ctarc.2025.101064
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00